169 related articles for article (PubMed ID: 19307693)
1. Effects of aldosterone on coronary function.
Benard L; Milliez P; Ambroisine ML; Messaoudi S; Samuel JL; Delcayre C
Pharmacol Rep; 2009; 61(1):58-66. PubMed ID: 19307693
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone, mineralocorticoid receptor, and heart failure.
Messaoudi S; Azibani F; Delcayre C; Jaisser F
Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone: effects on the kidney and cardiovascular system.
Briet M; Schiffrin EL
Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Lother A; Moser M; Bode C; Feldman RD; Hein L
Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
[TBL] [Abstract][Full Text] [Related]
5. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
[TBL] [Abstract][Full Text] [Related]
6. The endothelin-aldosterone axis and cardiovascular diseases.
Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
Jewell CW; Watson LE; Mock J; Dostal DE
Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
[TBL] [Abstract][Full Text] [Related]
8. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of aldosterone in the cardiovascular system.
Rocha R; Funder JW
Ann N Y Acad Sci; 2002 Sep; 970():89-100. PubMed ID: 12381544
[TBL] [Abstract][Full Text] [Related]
10. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone.
Lemarié CA; Paradis P; Schiffrin EL
J Mol Med (Berl); 2008 Jun; 86(6):673-8. PubMed ID: 18368382
[TBL] [Abstract][Full Text] [Related]
11. Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?
Lyngsø KS; Assersen K; Dalgaard EG; Skott O; Jensen BL; Hansen PB
J Cardiovasc Pharmacol; 2016 Jul; 68(1):1-10. PubMed ID: 26657712
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
Jaffe IZ; Mendelsohn ME
Circ Res; 2005 Apr; 96(6):643-50. PubMed ID: 15718497
[TBL] [Abstract][Full Text] [Related]
13. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
Horký K
Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
[TBL] [Abstract][Full Text] [Related]
14. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Chrissobolis S
Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells.
Ambroisine ML; Favre J; Oliviero P; Rodriguez C; Gao J; Thuillez C; Samuel JL; Richard V; Delcayre C
Circulation; 2007 Nov; 116(21):2435-43. PubMed ID: 17984374
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor and cardiac arrhythmia.
Gravez B; Tarjus A; Jaisser F
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
[TBL] [Abstract][Full Text] [Related]
17. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Zannad F; Radauceanu A
Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
[TBL] [Abstract][Full Text] [Related]
18. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G
Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330
[TBL] [Abstract][Full Text] [Related]
20. Why are mineralocorticoid receptor antagonists cardioprotective?
Chai W; Danser AH
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
